People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Another natural method that may help you find relief from environmental factors behind your post-nasal drip is by inhaling ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

People in Phoenix suffering from severe depression now have a Ketamine-derived nasal spray available for treatment.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study ...